Curis, Inc. ("Curis") , a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and ...
This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and... corporate communications solutions . With broad reach and a seasoned team of ...
People with a high number of antiseizure medications seem to be at risk for accelerated neuroaxonal loss. HealthDay News — In people with epilepsy, progression of retinal neuroaxonal loss is ...
This important paper takes a novel approach to the problem of automatically reconstructing long-range axonal projections from stacks of images. The key innovation is to separate the identification of ...